2. Signaling Pathways
  3. Immunology/Inflammation
    Metabolic Enzyme/Protease
  4. Arginase

Arginase

Arginase

Related Products

PDF 0.18 MB

Arginase (ARG) is an enzyme involved in urea cycle, where it catalyzes the hydrolysis of L-arginine into L-ornithine and urea. There are two distinct isoforms of arginase, arginase I and II, which are encoded by separate genes and display differences in tissue distribution, subcellular localization, and molecular regulation. Arginase activity has two major homeostatic purposes: first, to rid the body of ammonia through urea synthesis, and second, to produce ornithine, the precursor for polyamines and prolines. Polyamines produced through ornithine decarboxylase (ODC) are necessary for cell proliferation and regulation of several ion channels. Proline produced through ornithine aminotransferase (OAT) is necessary for production of collagen.

Arginase I is a cytosolic enzyme that is abundantly expressed in the liver and plays an essential role in hepatic urea cycle. In contrast, arginase II is a mitochondrial enzyme that is widely expressed outside the liver, most prominently in the kidney and prostate. Arginase functions important for protection against NH3 toxicity and cell growth and repair. Excessive arginase activity in mammals has been associated with cardiovascular and nervous system dysfunction and disease. Two relevant aspects of this elevated activity may be involved in these disease states. First, excessive arginase activity reduces the supply of L-arginine needed by nitric oxide (NO) synthase to produce NO. Second, excessive production of ornithine leads to vascular structural problems and neural toxicity. In addition, Arginase is a potential therapeutic target for the treatment of sexual arousal disorders in men and women.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-N0717S1
    L-Valine-13C5,15N
    		Inhibitor 98.0%
    L-Valine-13C5,15N ((S)-Valine-13C5,15) is the 13C- and 15N-labeled L-Valine (HY-N0717). L-Valine ((S)-Valine) is a nonlinear semiorganic material. L-Valine causes lipid peroxidation and accumulation of malondialdehyde (MDA), exhibits inhibitory activity against cyanobacteria. L-Valine inhibits multidrug-resistant bacteria through activation of PI3K/Akt signaling pathway and inhibition of arginase.
    L-Valine-<sup>13</sup>C<sub>5</sub>,<sup>15</sup>N
  • HY-W010510
    DL-Norvaline
    		Inhibitor 98.0%
    DL-Norvaline, a derivative of L-norvaline, L-norvaline is a non-competitive inhibitor of arginase.
    DL-Norvaline
  • HY-145331A
    ARG1-IN-1 hydrochloride
    		Inhibitor
    ARG1-IN-1 (example 1) hydrochloride is a human arginase 1 inhibitor with an IC50 of 29 nM.
    ARG1-IN-1 hydrochloride
  • HY-112885A
    nor-NOHA acetate
    		Inhibitor ≥99.0%
    nor-NOHA acetate (Nω-Hydroxy-nor-L-arginine acetate) is a specific and reversible arginase inhibitor, induces apoptosis in ARG2-expressing cells under hypoxia but not normoxia. Anti-leukemic activity, effective in endothelial dysfunction, immunosuppression and metabolism.
    nor-NOHA acetate
  • HY-W142432
    Perfluoroundecanoic acid
    		Activator 99.85%
    Perfluoroundecanoic acid is a perfluoroalkyl substance (PFAS). Perfluoroundecanoic acid is an orally active oxidative stress inducer. Perfluoroundecanoic acid promotes macrophage M2 polarization, activates Wnt/β-catenin signaling and enhances β-catenin nuclear accumulation. Perfluoroundecanoic acid -induced M2 phenotype macrophage accelerates tumor progression in vitro and in vivo. Perfluoroundecanoic acid induces DNA damage, reproductive and pathophysiological dysfunctions via oxidative stress in male Swiss mice. Perfluoroundecanoic acid inhibits Leydig cell development in pubertal male rats via inducing oxidative stress and autophagy. Perfluoroundecanoic acid accelerates insulitis development in a mouse model of type 1 diabetes. Perfluoroundecanoic acid can be used for the study of ovarian cancer, type 1 diabetes and inflammation.
    Perfluoroundecanoic acid
  • HY-155108
    OATD-02
    		Inhibitor
    OATD-02 is an orally active, competitive, reversible, noncovalent dual inhibitor of Arginase1 and 2. OATD-02 is a slow offset inhibitor, blocking intracellular arginases with IC50s of 20 nM (hARG1), 39 nM (hARG2), 39 nM (mARG1), and 28 nM (rARG1), respectively. OATD-02 abolishes tumor immunosuppression induced by both arginases. OATD-02 can be used for melanoma study.
    OATD-02
  • HY-145331
    ARG1-IN-1
    		Inhibitor
    ARG1-IN-1 (example 1) is a human arginase 1 inhibitor with an IC50 of 29 nM.
    ARG1-IN-1
  • HY-126332
    NED-3238
    		Inhibitor
    NED-3238 is a highly potent arginase I and II inhibitor with IC50 values of 1.3 nM and 8.1 nM, respectively.
    NED-3238
  • HY-N0717S9
    L-Valine-15N,d8
    		Inhibitor
    L-Valine-15N,d8 ((S)-Valine-15N,d8) is the deuterium and 15N labeled L-Valine (HY-N0717). L-Valine ((S)-Valine) is a nonlinear semiorganic material. L-Valine causes lipid peroxidation and accumulation of malondialdehyde (MDA), exhibits inhibitory activity against cyanobacteria. L-Valine inhibits multidrug-resistant bacteria through activation of PI3K/Akt signaling pathway and inhibition of arginase.
    L-Valine-<sup>15</sup>N,d<sub>8</sub>
  • HY-N0717S2
    L-Valine-13C5,15N,d8
    		Inhibitor
    L-Valine-13C5,15N,d8 ((S)-Valine-13C5,15N,d8) is the deuterium, 13C-, and 15N-labeled L-Valine (HY-N0717). L-Valine ((S)-Valine) is a nonlinear semiorganic material. L-Valine causes lipid peroxidation and accumulation of malondialdehyde (MDA), exhibits inhibitory activity against cyanobacteria. L-Valine inhibits multidrug-resistant bacteria through activation of PI3K/Akt signaling pathway and inhibition of arginase.
    L-Valine-<sup>13</sup>C<sub>5</sub>,<sup>15</sup>N,d<sub>8</sub>
  • HY-N0717S5
    L-Valine-2-13C
    		Inhibitor
    L-Valine-2-13C ((S)-Valine-2-13C) is the 13C-labeled L-Valine (HY-N0717). L-Valine ((S)-Valine) is a nonlinear semiorganic material. L-Valine causes lipid peroxidation and accumulation of malondialdehyde (MDA), exhibits inhibitory activity against cyanobacteria. L-Valine inhibits multidrug-resistant bacteria through activation of PI3K/Akt signaling pathway and inhibition of arginase.
    L-Valine-2-<sup>13</sup>C
  • HY-161061
    Arginase inhibitor 7
    		Inhibitor
    Arginase inhibitor 7 (compound A17) is an arginase (ARG1) inhibitor, with an IC50 of 0.16 μM. Arginase inhibitor 7 has high oral bioavailability.
    Arginase inhibitor 7
  • HY-N0717S8
    L-Valine-d1
    		Inhibitor
    L-Valine-d1 ((S)-Valine-d1) is the deuterium labeled L-Valine (HY-N0717). L-Valine ((S)-Valine) is a nonlinear semiorganic material. L-Valine causes lipid peroxidation and accumulation of malondialdehyde (MDA), exhibits inhibitory activity against cyanobacteria. L-Valine inhibits multidrug-resistant bacteria through activation of PI3K/Akt signaling pathway and inhibition of arginase.
    L-Valine-d<sub>1</sub>
  • HY-19548
    BEC
    		Inhibitor
    BEC, an arginine analogue, is a slow-binding competitive inhibitor of the binuclear manganese metalloenzyme arginase. BEC enhances substrate flux to NO synthase, thereby enhancing NO-dependent smooth muscle relaxation in the corpus cavernosum, and enhances penile erection.
    BEC
  • HY-118371
    Arginase inhibitor 2
    		Inhibitor
    Arginase inhibitor 2 is an Arginase inhibitor (Page 130 in reference patent). Arginase inhibitor 2 synergizes with adoptively transferred antigen- specific T cells to inhibit tumor growth.
    Arginase inhibitor 2
  • HY-N0717S3
    L-Valine-13C5,15N,d2
    		Inhibitor
    L-Valine-13C5,15N,d2 ((S)-Valine-13C5,15N,d2) is the deuterium, 13C-, and 15N-labeled L-Valine (HY-N0717). L-Valine ((S)-Valine) is a nonlinear semiorganic material. L-Valine causes lipid peroxidation and accumulation of malondialdehyde (MDA), exhibits inhibitory activity against cyanobacteria. L-Valine inhibits multidrug-resistant bacteria through activation of PI3K/Akt signaling pathway and inhibition of arginase.
    L-Valine-<sup>13</sup>C<sub>5</sub>,<sup>15</sup>N,d<sub>2</sub>
  • HY-N11451
    Lacto-N-fucopentaose III
    		Activator
    Lacto-N-fucopentaose III (LNFP-III) is an immune modulator. Lacto-N-fucopentaose III reduces the severity of experimental autoimmune encephalomyelitis (EAE) and CNS inflammation.
    Lacto-N-fucopentaose III
  • HY-173041
    Arginase inhibitor 9
    		Inhibitor
    Arginase inhibitor 9 (Compound 12a) is an arginase inhibitor with IC50 values of 9 μM and 55 μM for bovine and human arginase I, respectively. Arginase inhibitor 9 exhibits antioxidant activity and can scavenge free radicals. Additionally, Arginase inhibitor 9 can effectively regulate the levels of collagen and procollagen, exerting an anti-fibrotic effect.
    Arginase inhibitor 9
  • HY-Y0399S
    L-Norvaline-d5
    		Inhibitor
    L-Norvaline-d5 is the deuterium labeled L-Norvaline. L-Norvaline is the inhibitor for arginase, that promotes the production of NO, reduces oxidative stress, improves insulin resistance, and exhibits antioxidant and anti-hyperglycemic effects. L-Norvaline can be used in research of Alzheimer’s disease.
    L-Norvaline-d<sub>5</sub>
  • HY-112885
    nor-NOHA
    		Inhibitor
    nor-NOHA is a selective and reversible arginase inhibitor. nor-NOHA induces apoptosis in ARG2-expressing cells under hypoxia. nor-NOHA has anti-leukemic activity. nor-NOHA can used in study of endothelial dysfunction, immunosuppression and metabolism.
    nor-NOHA
Cat. No. Product Name / Synonyms Application Reactivity